Revolution Medicines, Inc. Stock Price, News & Analysis

Revolution Medicines (Nasdaq: RVMD) reported Q2 2025 financial results and corporate updates, highlighting significant progress in its oncology pipeline. The company's lead drug daraxonrasib received FDA Breakthrough Therapy Designation for PDAC treatment, with Phase 3 trial RASolute 302 expected to complete enrollment this year. A major financial milestone includes securing a $2 billion flexible funding agreement with Royalty Pharma.

The company reported Q2 2025 financial results with a net loss of $247.8 million (vs $133.2 million in Q2 2024), R&D expenses of $224.1 million, and G&A expenses of $40.6 million. Cash position stands at $2.1 billion, including $250 million from Royalty Pharma. Full-year 2025 projected GAAP net loss is estimated between $1.03-1.09 billion.

Multiple clinical programs are advancing, including elironrasib's FDA Breakthrough Therapy Designation for NSCLC treatment and promising developments with zoldonrasib for KRAS G12D mutations.

Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, will release its Q2 2025 financial results on August 6, 2025, after market close.

The company's senior management will host a webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss quarterly results and provide corporate updates. The webcast will be accessible through the company's investor relations website, with a replay available for at least 14 days following the live presentation.

Revolution Medicines (NASDAQ:RVMD) announced the publication of a peer-reviewed paper in Science detailing the discovery and development of zoldonrasib, their RAS(ON) G12D-selective covalent inhibitor. The drug targets RAS G12D mutations, which are present in 92% of pancreatic cancer, 50% of colorectal cancer, and 30% of non-small cell lung cancer cases.

The paper highlights zoldonrasib's novel tri-complex inhibitor mechanism, which creates a neomorphic protein-protein interface between cyclophilin A and activated RAS to selectively target RAS(ON) G12D proteins. Preclinical data showed significant tumor regression in multiple tumor types with KRAS G12D mutations.

The drug is currently being evaluated in clinical trials, including the RMC-9805-001 Phase 1 study for patients with advanced solid tumors harboring KRAS G12D mutations.

Revolution Medicines (NASDAQ:RVMD) announced that the FDA has granted Breakthrough Therapy Designation to its drug elironrasib for treating adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) who have received prior chemotherapy and immunotherapy but haven't been treated with a KRAS G12C inhibitor.

The designation is based on promising results from the Phase 1 RMC-6291-001 clinical trial, which demonstrated competitive antitumor activity, differentiated safety profile, and compelling objective response rate and progression-free survival. Elironrasib targets the RAS(ON) form of RAS G12C variant, present in approximately 12% of NSCLC cases.

This breakthrough designation aims to expedite development and review of the drug, addressing a significant unmet medical need in NSCLC, which accounts for 80%-85% of all lung cancers.

Revolution Medicines (Nasdaq: RVMD) and Iambic Therapeutics have announced a multi-year technology and research collaboration to develop novel drug candidates using Iambic's AI-driven discovery platform. The partnership centers on training custom versions of Iambic's NeuralPLexer model using Revolution Medicines' proprietary data and structures.

As part of the agreement, Iambic will receive up to $25 million in upfront and near-term performance-based milestone payments, plus ongoing R&D reimbursements. Both companies will have access to the improved models and retain rights to exclusive targets for independent pursuit.

Revolution Medicines (Nasdaq: RVMD) and Summit Therapeutics (Nasdaq: SMMT) have announced a clinical collaboration to evaluate combinations of Revolution's RAS(ON) inhibitors with Summit's ivonescimab in RAS mutant tumors. The collaboration will focus on three key compounds from Revolution Medicines: daraxonrasib (RMC-6236), zoldonrasib (RMC-9805), and elironrasib (RMC-6291).

The study will evaluate these combinations across three priority tumor types: RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC). Under the agreement, Summit will supply ivonescimab while Revolution Medicines will sponsor the study. Both companies will maintain commercial rights to their respective compounds, and the agreement is mutually non-exclusive.

Initial evidence has shown that daraxonrasib and elironrasib can safely deliver additive antitumor activity when combined with a PD-1 antibody in first-line treatment of patients with RAS mutant non-small cell lung cancer.

Revolution Medicines (Nasdaq: RVMD) has secured a $2 billion flexible funding agreement with Royalty Pharma to advance its RAS(ON) inhibitor portfolio for RAS-addicted cancers. The deal comprises up to $1.25 billion in synthetic royalty and up to $750 million in corporate debt.

The synthetic royalty portion includes five $250 million tranches, with the first $250 million received at closing and the second tranche tied to positive Phase 3 trial results. The royalty rates are tiered based on sales, reaching zero for sales above $8 billion. The debt facility consists of three $250 million tranches linked to daraxonrasib commercialization, with the first tranche available upon FDA approval.

This strategic funding allows Revolution Medicines to maintain full control over product development and commercialization while significantly expanding its financial resources.

Revolution Medicines (NASDAQ: RVMD) has received FDA Breakthrough Therapy Designation for daraxonrasib, targeting previously treated metastatic pancreatic cancer with KRAS G12 mutations. The designation is based on promising Phase 1 trial data and aims to expedite development and review of this potential treatment. The company is currently conducting RASolute 302, a Phase 3 registrational study expected to complete enrollment in 2025, with results anticipated in 2026. The study focuses on patients with pancreatic ductal adenocarcinoma (PDAC), where over 90% of cases carry RAS mutations, with approximately 85% specifically having KRAS G12 mutations. The trial's dual primary endpoints include progression-free survival and overall survival in the core patient population.

Revolution Medicines (RVMD) has initiated dosing in RASolve 301, a global Phase 3 clinical trial evaluating daraxonrasib against docetaxel chemotherapy in previously treated RAS mutant non-small cell lung cancer (NSCLC) patients. The trial will enroll approximately 420 patients who have received 1-2 prior therapies. The study focuses on patients with NSCLC carrying RAS mutations at position G12 (core population) and other specific RAS mutations (expanded population). Daraxonrasib targets RAS mutations present in 30% of NSCLC cases. The trial's dual primary endpoints are progression-free survival and overall survival in the core population. The decision to proceed with Phase 3 was based on promising early evidence from a single-arm trial showing acceptable safety and encouraging antitumor activity.